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A B S T R A C T
Supramolecular gels have recently emerged as promising biomaterials for the delivery of a wide range of
bioactive molecules, from small hydrophobic drugs to large biomolecules such as proteins. Although it has been
demonstrated that each encapsulated molecule has a different release profile from the hydrogel, so far diffusion
and steric impediment have been identified as the only mechanisms for the release of molecules from supra-
molecular gels. Erosion of a supramolecular gel has not yet been reported to contribute to the release profiles of
encapsulated molecules. Here, we use a novel nucleoside-based supramolecular gel as a drug delivery system for
proteins with different properties and a hydrophobic dye and describe for the first time how these materials
interact, encapsulate and eventually release bioactive molecules through an erosion-based process. Through
fluorescence microscopy and spectroscopy as well as small angle X-ray scattering, we show that the encapsulated
molecules directly interact with the hydrogel fibres - rather than being physically entrapped in the gel network.
The ability of these materials to protect proteins against enzymatic degradation is also demonstrated here for the
first time. In addition, the released proteins were proven to be functional in vitro. Real-time fluorescence mi-
croscopy together with macroscopic release studies confirm that erosion is the key release mechanism. In vivo,
the gel completely degrades after two weeks and no signs of inflammation are detected, demonstrating its in vivo
safety. By establishing the contribution of erosion as a key driving force behind the release of bioactive mole-
cules from supramolecular gels, this work provides mechanistic insight into the way molecules with different
properties are encapsulated and released from a nucleoside-based supramolecular gel and sets the basis for the
design of more tailored supramolecular gels for drug delivery applications.
1. Introduction
Hydrogels for biomedical applications such as tissue engineering
and drug delivery are widely reported [1–3]. Hydrogels are tradition-
ally divided into polymeric gels that consist of covalently cross-linked
polymer networks and supramolecular gels, consisting of fibrillar net-
works formed through non-covalent interactions [4]. Recently, supra-
molecular gels have attracted significant attention in drug delivery,
especially in the delivery of biologics [5], where they have demon-
strated numerous advantages over polymer based gels including the
fine tuning of their properties through different stimuli; self-healing;
and, mostly involve mild conditions of gelation that do not compromise
the stability of sensitive biopharmaceutical molecules such as proteins
and nucleic acids during encapsulation [6–8]. On the other hand, the
crosslinking of polymeric gels can involve harsh conditions of gelation
such as UV light or low pH to initiate cross-linking or the use of solvents
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which has been proven detrimental for the functionality of bio-
pharmaceuticals [9].
Bioinspired gelators based on peptides [10] and nucleic acids are
popular candidates for drug delivery systems [7,11] because of their
inherent biocompatibility due to their high water content and their self-
healing properties [7]. For example Puramatrix®, a self-assembling
acetyl-(Arg-Ala-Asp-Ala)₄-CONH₂ peptide that forms a stable hydrogel
after increasing the pH and the ionic strength, has been employed for a
broad range of clinical applications and has successfully delivered
several biologically-active agents such as proteins (growth factors, cy-
tokines, insulin or antibodies) and siRNA in preclinical in vivo studies
[12–14]. Peptide-based gels, however, have been shown to be suscep-
tible to proteolytic enzymatic degradation and chemical modifications
are necessary to improve their biostability [15–17]. Nucleoside-based
gelators are proposed as a novel alternative modality that would be
stable against proteolytic enzymes.
Nucleoside-based gels have recently been introduced as injectable
delivery systems that can reform in situ after injection at the site of
action [18], delivering different classes of molecules from small ther-
apeutic molecules to macromolecules such as proteins and nucleic acids
[19,20]. For example, a guanosine-5′-hydrazide gel was able to en-
capsulate various pharmacologically active molecules such as acyclovir,
vitamin C and vancomycin [21], whereas a 5′-deoxy-5′-iodoguanosine
gel was reported to incorporate antivirals [22]. Additionally, Kaplan
et al. demonstrated that a thymidine-based mechanoresponsive hy-
drogel can be used for the delivery of antibodies [19]. A urea based-
bolamphiphile was found to avoid the foreign body reaction after in vivo
injection, demonstrating the ability of these types of gels to be im-
munocompatible [18]. Ramin et al. reported the sustained release of a
small hydrophobic fluorescent dye and a fluorescently labelled protein
through a nucleotide lipid containing thymidine and 1,2 –dipalmitoyl-
sn-glycerol phosphate paired with different cations with no toxicity in
vivo [20]. Additionally this hydrogel was shown to protect the integrity
of the model protein in vivo for a period of a few days compared to the
non-formulated protein, successfully demonstrating the potential of
these materials. Interestingly, the authors reported that, despite their
size, the small hydrophobic molecule was released more slowly com-
pared to the larger, more hydrophilic protein, raising questions over the
influence that the properties of the molecules of interest can have on
the encapsulation mechanism and the release behaviour of the final
formulation.
Proteins are complex macromolecules with a diversity of chemical
groups exposed on the surface or buried in their core depending on the
nature of the surrounding environment. Two major properties that
define their behavior in solution are their molecular weight (MW) and
charge. Until now, protein release from supramolecular gels has been
demonstrated to be strongly influenced by the proteins' MW and charge
[23–25]. Mechanisms that have been identified to control the release of
proteins from supramolecular gels including diffusion, electrostatic in-
teractions and steric impediment through the hydrophilic pores created
by the 3D nanofiber scaffold of the hydrogel [23–25]. In addition, our
work [26] and that of others [27–29] has demonstrated that proteins
encapsulated in supramolecular gels can be immobilised by the nao-
nofiber scaffold through interactions with the hydrophobic core of the
gel nanofibers. Hence, we postulate that this interaction of the protein
with the gel nanofiber could have a significant effect on the protein
release profile and, if this is the case, that the mechanism of protein
release will be dominated by an erosion process. To date erosion based
mechanisms have only been demonstrated for polymer hydrogels but
not for supramolecular gels [9,30,31].
Herein, we use the well characterised, self-healing nucleoside-based
hydrogelator N4-octanoyl-2′-deoxycytidine [32,33] developed in our
group (SI, Fig. S1), to encapsulate a broad range of molecules (a small
hydrophobic molecule and several proteins) and characterize its per-
formance as a drug delivery system in vivo and in vitro. This nucleoside-
based gelator was previously shown to encapsulate a hydrophobic dye
(model molecule for hydrophobic drugs) selectively into the hydro-
phobic core of the fibers [33]. Although others in the field have used
nucleoside gelators for protein delivery [19,20], the novelty of this
work is that we mechanistically investigate how proteins with different
properties associate with the gel nanofibers and, for the first time for a
supramolecular gel, we report the detailed mechanism of encapsulation
and release of therapeutically relevant molecules and erosion of the gel.
After release, we demonstrate that functional proteins (lysozyme and
insulin) retain their biological activity in vitro. Furthermore, the ability
of the gel to improve the stability of a model protein in the presence of
proteolytic enzymes compared to the protein alone is demonstrated for
the first time. Finally, the release of a small hydrophobic dye and a
fluorescently labeled protein as well as their effect on the gel de-
gradation profile are studied in vitro and in vivo.
2. Results and discussion
2.1. Encapsulation of proteins in hydrogels
In order to investigate the potential of the hydrogel to act as a drug
delivery system for the controlled release of different proteins we in-
corporated four model proteins into the gel (SI, Fig. S2). Bovine Serum
Albumin (BSA), β-lactoglobulin (β-lact) and insulin (ins) are negatively
charged at physiological pH (PBS, pH 7.4) but possess different MWs
whereas β-lactoglobulin and lysozyme (lys) have similar/comparable
MWs but are negatively and positively charged, respectively, at phy-
siological pH. Stable gels were obtained after encapsulation of all
proteins, (SI, Fig. S3).
This hydrogelator has been previously reported to be self-healing
[32]. This is an important condition for the syringeability of the gel and
its ability to reform in situ. Rheology measurements have been ex-
tensively used in the literature to simulate the shear stress during
syringing [18,24,32]. Here, we perform time dependent rheology
measurements (SI, Fig. S4) which confirm that the presence of the
protein is not preventing the ability of the gel to self-heal.
After establishing that a self-healing supramolecular gel can be
formed with the N4-octanoyl-2′-deoxycytidine gelator in the presence
of proteins with different MWs and charge we investigated how the
proteins were entrapped within the gel. Previous literature has de-
monstrated that peptide based supramolecular hydrogels can im-
mobilise proteins through the interaction of the protein with the hy-
drophobic core of the nanofiber [27–29] but physical entrapment of the
proteins in the hydrophilic cavities of the nanofibrous gel network may
also be possible in our system.
2.1.1. Protein-gel fibre association
In order to investigate the location of the proteins in the gel and
elucidate the interaction between nanofibers and proteins we used
fluorescence microscopy to image fluorescamine labelled proteins.
Fluorescamine is a well-established dye in protein quantification as it
reacts with primary amines and forms fluorescent complexes, conse-
quently it is selective for the proteins and not the gelator [34]. In the
presence of the labelled proteins, fibrous structures can be observed
(Fig. 1) that are similar in appearance to the fibrous structure of the gel
that was reported before [32]. As the gel fibers alone are not fluorescent
(at λex = 405 nm), the observation of fibres can be assumed to be
caused by the association of fluorescent proteins with the gel fibre
network. The dispersed points giving strong fluorescence signals across
the fibre network are likely due to protein and/or dye associated with
fibre bundles (crossover points) or dye/protein aggregates. Note that
the size of the observed features does not correspond to their actual
dimensions. The diameters of the fibers (254 nm) observed in fluores-
cence microscopy were considerably larger than expected (∼13 nm)
[33] which is attributed to instrumental limitations (Raleigh/Abbe
criteria, signal to background and signal to noise (of the detector)
ratio).
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2.1.2. Hydrophobic protein-gel fibre interactions
The intrinsic fluorescence of both the proteins and the gel was used
for further evaluation of the interaction of the protein with the fibers
[35]. The protein’s intrinsic fluorescence is due to the presence of
aromatic amino acids and a change in their surrounding environment
can result in a change in the fluorescence intensity or emission maxima
[35]. The gelator is non-fluorescent in solution but it fluoresces in the
self-assembled state, as previously reported [33]. As presented in Fig. 2,
emission spectra were recorded for the gel after the encapsulation of the
proteins, the gel and the proteins alone, after excitation at two wave-
lengths that have been widely used for the excitation of proteins,
275 nm for the general excitation of the three aromatic amino acids and
295 nm for the specific excitation of tryptophan (human insulin has no
tryptophan, so no emission after excitation at 295 nm is detected).
Compared to the spectra obtained from protein solutions, the
fluorescence emission spectra of all four different proteins in the gels
shift and fully overlap with the emission spectra of the gel without the
proteins. This suggests that the protein’s intrinsic fluorescence is fully
quenched due to their association with the fibers and only the fluor-
escence of the gel is detected. This may be the result of a change in the
environment of the aromatic amino acids in the protein structure and
indicates that these aromatic amino acids are directly involved in the
fiber-protein interactions.
2.1.3. Small angle X-ray scattering studies
To understand if the presence of the protein is affecting the structure
of the fibres, we performed small angle X-ray scattering (SAXS) mea-
surements of the gels with proteins, the proteins in solution and the gel
alone to determine the gel fiber diameters (Figs. 3 and SI S6). SAXS has
been previously used to investigate the structures of supramolecular
gels [33,36,37] as well as the effect that molecules encapsulated in the
fiber have on the fiber diameter [38]. The gel sample was fitted to a
flexible cylinder model (as previously reported for similar systems)
[38], revealing a fiber radius of 73.2 Å, in good agreement with pre-
viously published data [33]. Since fluorescence microscopy images
showed that the proteins locate themselves on the fibres yielding cy-
lindrical geometries, the SAXS patterns obtained from protein con-
taining gels were fitted to a flexible cylinder model in the same manner
as the gel sample that did not contain proteins, yielding fibre radii of
91.2 ± 0.4 Å (BSA), 66.6 ± 0.4 Å (β-lactoglobulin), 71.1 ± 0.9 Å
(lysozyme) and 67.6 ± 0.9 Å (insulin). The fitting parameters are
presented in SI, Table S1. All fiber diameters cluster around the same
range of values except that for the BSA containing gel. This indicates
that there is an ordered association of BSA with the fiber. The other
proteins likely associate with the fibers by arranging themselves in a
non-ordered, amorphous structure surrounding the main gel fiber
which would not be detectable by X-ray scattering. Together, the
fluorescence microscopy and spectroscopy as well as the SAXS data (for
BSA) provide complementary evidence that the proteins are not loosely
entrapped in hydrophilic cavities between the gel fibres. Instead, the
proteins engage in interactions with the gel fibers that result in a close
association and co-localisation of the proteins and the fibers.
2.2. Prevention of protein enzymatic degradation
As one of the main drivers of protein encapsulation in gels is to
protect them from enzymatic degradation, we subsequently evaluated
whether the protein-gel association could be beneficial in preventing
enzymatic degradation of the proteins. We have previously shown that
the nucleoside gels used here are able to protect proteins from pH in-
duced denaturation [26]. The ability of gels to provide protection
against enzymatic degradation has been extensively suggested but
never clearly demonstrated. Here, we exposed the BSA containing gels
to two model proteolytic enzymes, α-chymotrypsin [39] and pepsin
[40]. These enzymes are encountered in the human body, are readily
available and inexpensive. Bovine Serum Albumin was chosen as the
model protein due to its relative high molecular weight that would
allow for a clear demonstration of the protein breakdown into shorter
protein fragments in SDS-PAGE separation.
Samples of gels containing proteins (G) and samples of the protein
Fig. 1. Fluorescence images of gels (concentration 0.5% w/v) (left column) and
solutions (right column) containing (30 μM) protein labelled with fluor-
escamine in PBS for 4 h at 37 °C; BSA, β-lactoglobulin, lysozyme, insulin and gel
alone (from top to bottom). The 405 nm laser was set to 0.8%, emission de-
tected at: 490–624 nm, channel colour (LUT) was set to green. (For inter-
pretation of the references to colour in this figure legend, the reader is referred
to the web version of this article).
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in solution alone (P) were incubated for different time periods (1 h, 4 h
and 1 day) in the presence of enzymes before analysing them using SDS-
PAGE (Fig. 4). When the band that corresponds to BSA (highlighted in
Fig. 4) was compared between samples containing protein only and
protein in the presence of the gel, it is evident that for both enzymes the
band intensity and hence the amount of intact protein for the protein
alone was notably lower than for the protein/gel sample at all time
points. At the later time points, the band intensity faded for the protein
in the gel as well. This indicates that even though BSA degrades in both
samples, the degradation process is considerably slower in the gel
containing system, supporting the supposition that the presence of the
gel has a protective effect on enzymatic degradation. The eventual
decrease in the total amount of protein in the gel sample could be at-
tributed to enzymes slowly diffusing into the gel, BSA partially diffusing
out of the gel, the gel slowly eroding or a combination of all three
processes.
2.3. Protein release and gel erosion
The close association of the proteins with the gel fibres allows for
two possibile mechanisms (or a combination of both) of protein release
Fig. 2. Fluorescence emission spectra for gels
(at concentration 0.5% w/v) containing four
different proteins (30 μM) and the gel alone in
PBS (30 μM for all proteins in gel and solution,
apart from insulin which is 3 μM to allow re-
cording of samples of insulin in gel and solution
with the same instrumental settings). In every
graph, protein containing gel after excitation at
295 nm (black solid), protein containing gel
after excitation at 275 nm (green solid), protein
in solution after at 295 nm (black bold), protein
in solution after excitation at 275 nm (green
bold), gel without protein after excitation at
295 nm (black dashed), gel without protein
after excitation at 275 nm (green dashed). The
two minor peaks between 400 nm and 450 nm
on the spectra of the gels containing β-lacto-
globulin and insulin have been identified as
artefacts and are not related to the protein/gel
intrinsic fluorescence. (For interpretation of the
references to colour in this figure legend, the
reader is referred to the web version of this
article).
Fig. 3. Fibre radii determined from SAXS data obtained from gels (at con-
centration 0.5% w/v) with the four different proteins (30 μM) and the gel alone
in PBS at room temperature. The data points represent the average fitted values
of the radii and standard errors of the fitted values are also presented as error
bars.
Fig. 4. SDS-PAGE for BSA (30 μM) en-
capsulated in gels (G) and BSA alone (P) after
incubation with two different enzymes; chy-
motrypsin and pepsin for 1 h, 4 h and 1 day. In
120 μL of gel (0.5% w/v) in different buffers
(50 mM KH2PO4 (pH = 4.5) for pepsin and
PBS for chymotrypsin), 10 μL (5 mg/ml,
≥1250 units/mg) of pepsin and 20 μL (2 mg/
ml, ≥80 units/mg) of chymotrypsin were pi-
petted on top of the already formed gel and
incubated at 37 °C.
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from the system; dissociation of the protein from the fibers and diffu-
sion out of the gel or degradation of the gel structure where the
breakdown of the fiber structure ultimately results in the liberation of
the proteins. We therefore investigated the in vitro release of the same
set of proteins (BSA, β-lact, ins and lys) from the gels. Gels without
(Fig. 5A) and with the proteins (Fig. 5B) were brought in contact with
PBS at 37 °C and samples of the supernatant were taken at different
time points. The concentration of the proteins at each time point was
determined using the colorimetric Bradford assay, measuring the ab-
sorbance at 595 nm [41] and the gelator concentration was quantified
through its UV absorbance at 295 nm (Fig. 5A).
Interestingly, the release profiles of all proteins followed the same
trend, regardless of the different protein properties (Fig. 5B). Notably,
the release profile also matched the profile of the physical degradation
of the gel, suggesting that gel degradation may be a key release me-
chanism for proteins from this system. For polymeric gels both diffusion
and erosion/degradation have been reported to regulate the release
depending on the formulation [9]. For example, for Pluronic gels en-
capsulating the therapeutic proteins insulin [30] and IL-2 [31], it was
demonstrated that gel erosion underpins the release mechanism. To
date, for supramolecular gels the protein release mechanisms have been
identified as diffusion out of the gel, with contributions from electro-
static interactions and steric impediment [23–25] whereas gel erosion
has not been reported so far. Especially for supramolecular peptide-
based gels, it has been previously demonstrated that proteins with
different properties mainly diffused through the gel and had different
release profiles depending on their properties [24], whereas no data
have been reported so far on the release mechanism of nucleoside-based
gels. For this nucleoside-based gel, the correlation of the kinetics of the
protein release and gel degradation profile as well as the independence
of the release profile on the type of the encapsulated protein, strongly
suggest that erosion is the main mechanism by which proteins leave the
gel. Macroscopic images of the gel eroding over time are presented in
SI, Fig. S7.
In order to study the gel erosion on the nanoscale, we used Atomic
Force Microscopy (AFM). Gels not containing proteins were incubated
in PBS at 37 °C and after 4 h incubation samples drawn from the su-
pernatant were imaged with AFM at 37 °C in PBS. Individual fibers
were captured floating in the supernatant (Fig. 5C) demonstrating that
intact fibers leave the bulk gel during gel erosion in a biologically re-
levant environment. Complementary data using fluorescence imaging
that shows gel erosion in the presence of labelled BSA will be discussed
in a later section.
2.3.1. Investigating the released protein functionality
After evaluating that the gel provides sustained release a critical
question is whether the functionality of the protein is preserved after
encapsulation within the gel. This has also been a controversial topic
for the polymeric gels [9]. Firstly, the integrity of all released proteins
was tested with SDS-PAGE separation. As presented in Fig. 6A, all four
released proteins have the same molecular weight as the proteins that
did not undergo gel encapsulation (represented by the same band on
the SDS-PAGE). Furthermore, the protein functionality is highly de-
pendent on its secondary structure [42]. While circular dichroism
would be a typical choice to study the secondary structure of proteins,
in this system the strong CD activity of the gelator precludes the use of
CD for the protein characterisation [33]. Considering this, we included
a therapeutic protein, insulin and an enzyme, lysozyme in our study and
assessed their activity after encapsulation [43].
2.3.1.1. Insulin functionality. To assess the bioactivity of insulin after
the release through the gel, we used a cell-based functional assay. The
HepG2 cells originate from a human liver carcinoma (one main target
organ of insulin) and express abundant levels of the insulin receptor. A
luciferase vector was transfected under the promoter fragment of the
HMG CoA enzyme that is responsive to insulin [44–46]. The cell
response to different doses of released insulin and insulin in solution
was measured through luciferase activity. In Fig. 6B, insulin released
from the gel (red bars) is plotted against insulin in solution (green bars).
No difference between the bioactivity of the natural insulin and the
released insulin was observed and, importantly a clear dose-response
Fig. 5. Formation of stable, self-healing gels able to deliver different proteins in
a sustained way. (A) Release profiles of gel alone (grey trace) and (B) Release
profiles of different proteins from the gel; blue (BSA), β-lactoglobulin (red),
lysozyme (green), insulin (yellow) and gel alone (dashed grey trace). 0.5 ml of
protein containing (30 μM) gel (0.5% w/v) were incubated with 1 ml PBS at
37 °C. The protein concentration was determined at certain time points using a
Bradford assay at 595 nm [41]. The gelator concentration was determined at
295 nm. (C) AFM images of gel fibers (gel alone at concentration 0.5% w/v) on
mica imaged in the release medium (PBS) after 4 h incubation at 37 °C. 0.5 ml
of gel (0.5% w/v) were incubated with 1 ml PBS at 37 °C. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web
version of this article).
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was observed at ranges of concentration similar to those present in
humans, both at fasting (normal range 2–25 μUI/ml taken as a
reference the Mayo Clinic laboratory fasting values for the normal
population [47]) and at post-prandial levels (approximately 30–230
μIU/ml [48]). There was no action of the released insulin on the
mutated promoter bearing four point-mutations, where also there was
no action of the natural insulin, indicating that the response was
specific for the insulin receptor (SI, Fig. S8).
2.3.1.2. Lysozyme functionality. Lysozyme is an antimicrobial enzyme
that selectively cleaves β-1,4-glycosidic bonds between N-
acetylmuramic acid and N-acetylglucosamine present in bacterial cell
walls [49]. The functionality of lysozyme has been previously assessed
using Micrococcus lisodeikticus lyophilised cell walls as a substrate [43].
The lytic activities of the released lysozyme after encapsulation in the
gel and free lysozyme are presented in Fig. 6C. Both traces (green and
red) follow the same trend and are both distinctly different from the
control (black trace), demonstrating that released lysozyme has the
similar activity as free lysozyme. Incubation of the cells with the gelator
alone did not cause a change in absorbance, indicating that the gelator
does not affect the integrity of the cell wall and that a change in
absorbance in the gelator/protein sample is due to lysozyme released
from the gel.
2.4. Release of small molecules and proteins
Upon demonstrating the ability of this hydrogel to sustain con-
trolled release of functional proteins in vitro, we progressed to an as-
sessment of the protein release in vivo using a fluorescently labelled
protein (cyanine 5-BSA, Cy5-BSA). Our previous work has shown that a
small hydrophobic dye can be encapsulated in the hydrophobic core of
the fibers of this gelator [33]. Alongside the fluorescently labelled
protein, we therefore also tested the release of a fluorescent dye (1,1′-
dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate, Dil)
incorporated in the hydrophobic core of the nanofibers as a model for a
small molecule hydrophobic drug molecule. The fluorescent probes
were selected due to their good contrast in the In Vivo Imaging System
(IVIS)® we employed. The purpose of these experiments is to investigate
the release profiles of Cy5-BSA in vivo and the biocompatibility of the
gel. Before moving to the in vivo experiments, we monitored the Cy5-
BSA and Dil containing gels with fluorescence microscopy, in-
vestigating their release behaviour in vitro to help understand their in
vivo behaviour.
2.4.1. Fluorescently labelled protein and fluorescent dye release in vitro
Real time fluorescence microscopy was used to follow the release of
the encapsulated molecules from the gel in vitro. Gels containing either
Dil or Cy5-BSA were prepared and incubated in PBS at 37°C for 48 h.
Images were captured at t = 0 min, 10min, 24 h and 48 h and are
presented Fig. 7. For t = 0 min, the fluorescent molecules directly as-
sociate with the fibers in both samples. It is important to highlight again
that the gel alone was not fluorescent and the fluorescence signal can be
exclusively associated with the presence of the encapsulated molecule
(Cy5-BSA or Dil).
At t = 0 min, both samples show an extensive fluorescent network
of fibers with dispersed points giving strong fluorescence signals, most
likely due to protein and/or dye associated with fibre bundles (cross-
over points) or dye/protein aggregates (note that the size of the ob-
served features does not correspond to their actual dimensions due to
the method’s limitations). After 10 min, we focused on the gel-PBS in-
terface, where fluorescent fibers and protein aggregates were observed
to be present on the outside of the bulk gel, suggesting that the protein
aggregates were released from the gel (Fig. 7, zoom in at 10 min).
A similar observation was made with Dil encapsulated in the gel
where fluorescent fibers as well as dye aggregates are found on the
outside of the bulk gel. After 1 day, in both cases the bulk gel had been
fully eroded leaving smaller gel fragments floating in the medium. In
the case of Cy5-BSA, fluorescent structures of different sizes (< 20 μm)
and shapes were floating in the medium whereas in the case of Dil
encapsulating gel, significantly larger gel fragments were visible with
diameters of more than 100 μm, suggesting that fibers are held together
for longer in the latter. In the case of Dil encapsulating gel fragments,
fibers were protruding out from the gel phase into the gel-medium in-
terface, suggesting that interfacial erosion of the gel occurs through the
loss of single fibers from the gel phase (SI, Fig. S9).
This data corroborates the in vitro protein release data above
(Fig. 5B) that showed that the release of different encapsulated proteins
from the gel followed the degradation of the gel.
In the case of the encapsulated hydrophobic dye (Dil), in vitro re-
lease data were impossible to acquire due to the high hydrophobicity of
the dye that tended to interact strongly with the containers and not
remain in solution. Even when different solvents were used to extract
the dye, exact quantification was not possible. The use of an alternative
dye was not an option at this stage as in contrast to other dyes Dil
demonstrated selective binding into the hydrophobic cavity of the fi-
bers and provided adequate contrast for the subsequent IVIS® study.
Due to this, macroscopic images of the degradation of the gel en-
capsulating the dye and the gel alone are presented in Fig. S10, SI, over
a course of 24 h. As the volume of the gel encapsulating Dil and the gel
alone reduced in a similar manner over time, we assume that the release
of the dye follows the gel erosion as well and the gel completely de-
grades macroscopically within 1 day. The in vitro release data (Fig. 5B)
Fig. 6. SDS-PAGE of different proteins (30 μM) BSA, β-lactoglobulin (β-lact), lysozyme (lys), insulin (ins) after encapsulation in the gel (0.5% w/v). Data are
presented in pairs (first column control protein and second released protein). Dose response curve for human insulin was measured through luciferase activity; [50]
gel alone (black trace), insulin released from gel in the presence of gelator (red trace) and insulin alone (green trace) (N = 3 with 6 replicate measurements each).
Turbidimetric assay of lysozyme; absorbance at 460 nm of Micrococcus Lisodeikticus lyophilised cell walls in the presence of gel alone (black trace), released protein
(red trace) in the presence of gel, lysozyme control (green trace),(N = 3). (For interpretation of the references to colour in this figure legend, the reader is referred to
the web version of this article).
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are in good agreement with the fluorescence microscopy images that
show gel breakdown within 24 h. The fluorescence microscopy images
showed that the gel encapsulating the dye and the gel encapsulating the
protein followed two different breakdown pathways; the first broke
down into gel particles whereas the second into fibre bundles, sug-
gesting that the forces holding the fibers together for the gel
encapsulating the dye are stronger compared to the gel encapsulating
the protein.
2.4.2. Fluorescently labelled protein and fluorescent dye release in vivo
To obtain a preliminary insight into the safety of the material in vivo
and its potential as a drug delivery system, we performed IVIS® imaging
Fig. 7. Fluorescence microscopy images of gels (0.5% w/v) encapsulating Cy5-BSA at a final concentration of 15 μM (left) and hydrophobic dye (Dil) at a final
concentration of 8.3 μM (right) at after incubation with PBS at 37 °C at different time points (t = 0 min, 10 min, 24 h, 48 h). The arrows indicate the gel-PBS
interface. In each case a large area image (map) and a zoom in image were recorded. For the Cy5 labelled protein, 647 nm laser was set to 4%, emission detected at
654–752 nm, channel colour (LUT) was set to magenta; for Dil, 561 nm laser was set to 0.1%, emission detected at.561–624 nm.
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following similar studies in the literature [20]. To date, a limited
number of nucleoside-based gelators have been tested in vivo [18,20].
In this work, we used a nucleoside-based gel encapsulating a small
hydrophobic dye (Dil) or Cy5-BSA in order to evaluate the release of
these model molecules from the gel in vivo.
Hydrogels containing Cy5-BSA and Dil, Cy5-BSA in solution and gel
alone were injected subcutaneously into mice. In Fig. 8A, IVIS® images
of the mice are presented at different time points (0 h, 1 h, 24 h and 2
weeks after subcutaneous injection) for gels encapsulating Cy5-BSA
(top) and Dil (bottom). In both cases the fluorescence intensity faded
out over time and was almost zero after two weeks (very low levels of
fluorescence were detected probably due to association of the dye with
tissue). No control group was injected with Dil in solution as Dil is
highly hydrophobic and remains completely insoluble in PBS. Fluor-
escence data of the encapsulated molecules were extracted for quanti-
fication and are presented in Fig. 8B. In all cases there was an increase
in the fluorescence intensity of the encapsulated molecules during the
first 4 h, probably due to the gel reformation after the shear stress ap-
plied during injection. Another explanation could be equilibration
phenomena of the fluorescent probe in the lipophilic tissue environ-
ment that have been previously reported [51]. After this period,
fluorescence intensity started to drop as expected.
Fluorescence data of the gel containing Cy5-BSA and Cy5-BSA in
solution (Fig. 8B) suggests that encapsulation in the gel increased re-
tention of Cy5-BSA compared to Cy5-BSA in solution. In both cases, the
mice of both groups were healthy when sacrificed after 2 weeks and
there was no macroscopic trace of the gel in the tissue, indicating that
the gel is biodegradable in vivo (Fig. 8D).
2.5. Biocompatibility in vivo
In order to investigate if the gel causes any inflammation, cross-
sections of the tissue at the site of injection and surrounding the site of
injection of the gel alone were stained with haematoxylin and eosin
imaged as shown in Figs. 8D and S15. Tissue and cell morphology
throughout the entire area of all samples appeared comparable to the
control (Fig. S16). There was no evidence of the gel depot itself or of
cellular or tissue damage from the gel in the samples. Areas of hae-
morrhage or excessive immune cell infiltration (including cells such as
mononuclear leukocytes and polymorphonuclear cells) were not vi-
sualised within any of the tissues assessed. The basic histological in-
vestigations indicated no damage to the cells within the tissue where
the gel had resided. These samples were measured 2 weeks after in-
jection, therefore, at this stage we can conclude that no chronic in-
flammation or tissue necrosis was observed, suggesting that the mate-
rial does not cause any permanent damage to tissue. It is possible that
Fig. 8. In vivo data of gels encapsulating Dil
and Cy5-BSA after subcutaneous injection in
mice (N = 3 for each group); (A) IVIS® images
of the mice after injection of 300 μl of gel
(0.5% w/v) encapsulating Cy5-BSA (15 μM,
top row), Cy5-BSA in solution (15 μM) and gel
encapsulating a hydrophobic dye, Dil (8 μM).
Images are presented in the same colour scale
6.00 × 108 - 1.00 × 1010 (ρ/sec/cm2/sr) for
the gel encapsulating Cy5-BSA and Cy5-BSA in
solution and 3.50 × 108 - 7.00 × 109 (ρ/sec/
cm2/sr) for all the images of the gel with Dil.
(B) Normalised to maximum fluorescence in-
tensity (fluorescence signal is measured in ra-
diance over the same region of interest for all
images) of gel encapsulating Cy5-BSA (solid
trace) and Cy5-BSA in solution (dotted trace)
and gel encapsulating Dil (dashed trace)
(N = 3). (C) Macroscopic image of tissue
where control gel (without encapsulated mo-
lecule) was injected (D) Macroscopic image of
tissue where control gel (without encapsulated
molecule) was injected; after two weeks the
animals were sacrificed and the gel had com-
pletely degraded. No control group was in-
jected as Dil is highly hydrophobic and re-
mains completely insoluble in PBS. The
injection site is highlighted in red. (E)
Photomicrograph showing normal cellular and
tissue morphology. Haematoxylin and eosin
were used to stain the tissue at and around the
injection site 2 weeks after the injection of the
control gel (without encapsulated molecule).
Further photomicrographs and the control as
given in the SI -Figs. S15 and S16 respectively.
(For interpretation of the references to colour
in this figure legend, the reader is referred to
the web version of this article).
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an immune cell response could have been present in the days im-
mediately following injection as is usual following injections of bio-
materials [52–55].
3. Conclusions
Supramolecular gels have emerged as promising biomaterials for
drug delivery. Here, we demonstrate that nucleoside-based supramo-
lecular materials form stable, self-healing gels in the presence of in-
corporated proteins. We report for the first time that gel erosion plays a
key part in the release mechanism of proteins from a supramolecular gel
and provides indicative evidence that this erosion based release process
is related to the non-covalent association of proteins to the gel fibres.
Interestingly, the erosion-based release profile of the proteins is in-
dependent of the type of proteins used. Protection from enzymatic de-
gradation was shown to be a major advantage of these materials for
protein delivery. Additionally, after in vitro release, proteins (such as
lysozyme and insulin) are shown to maintain their functionality. In vivo
injection of the nucleoside based hydrogel resulted in no toxicity over
two weeks and no signs of inflammation were detected. This highlights
the suitability of supramolecular hydrogels to act as protective matrices
for protein delivery and suggests that they could be used to release
proteins in a manner that is independent of the nature of the proteins.
4. Experimental methods
4.1. Materials
2′-Deoxycytidine (lot #SLBN6031, 99% [high-performance liquid
chromatography (HPLC)]), pepsin from porcine gastric mucosa
(#P7012, lyophilized powder, ≥2,500 units/mg protein (E1%/280)),
lysozyme from chicken egg white lyophilized powder (product #
L6876, protein ≥90%, ≥40,000 units/mg protein), β-lactoglobulin B
from bovine milk (≥90% (PAGE) product # L8005), Bovine Serum
Albumin lyophilised powder, essentially fatty acid free and essentially
globulin free, ≥99% ((agarose gel electrophoresis), product #A028)
1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate
97% (product #468495) and fluorescamine [(product # 47614)
BioReagent, suitable for fluorescence, ≥99.0% (UV)], C4129 α-
Chymotrypsin from bovine pancreas, Type II, lyophilized powder, ≥40
units/mg protein, (product # C4129), Micrococcus lisodeikticus lyo-
philised cells, Dulbecco’s Phosphate Buffered Saline Modified, (without
calcium chloride and magnesium chloride, liquid, sterile-filtered, sui-
table for cell culture D8537) were purchased from Sigma Aldrich.
Polyacrylamide gels 4–20% Mini-PROTEAN® TGX™ Precast Protein
Gels, 12-well, 20 μl (#4561095) and Quick Start™ and Bradford 1x Dye
Reagent (#5000205) were purchased from Bio-Rad. Cyanine5 NHS
ester was purchased from Lumiprobe. Insuman Rapid 100 IU/ml solu-
tion for injection in a cartridge was purchased from Sanofi. SnakeSkin™
Dialysis Tubing was purchased from Thermofisher Scientific (Waltham,
Massachusetts, United States), MWCO 3.5 kDa. For Fluorescence
Microscopy Cellview cell culture slide (Item No.: 543079) were pur-
chased from Greiner Bio-one. The gelator was synthesized according to
previously published work. Analysis of the gelator was performed by
NMR and liquid chromatography–mass spectrometry (LC–MS)
(Supporting Information Figs. S12 and S13), and purity was determined
as 98% (LC–MS). [32]
4.2. Gel preparation
Certain amount of gelator was weighed out in 2 ml HPLC vial and
dispersed with PBS in order to get a final concentration of 0.5% w/v.
The vial was carefully sealed and the gelator was heated up to 100 °C
till complete dissolution. The sealed vial was immersed in a water bath
at 37 °C for 1 min before opening (allowing for water condensation)
and certain amount of protein was pipetted in to achieve final protein
concentration of 30 μM. For protein-gel association studies, stock so-
lutions of proteins were prepared in PBS (Bovine Serum Albumin
27 mg/ml, Lysozyme 5.75 mg/ml, β-lactoglobulin, Insulin 2 mg/ml)
and 40 μl of protein stock solution was pipetted into 500 μl of gelator at
37 °C. For the Real Time Fluorescence Microscopy and the in vivo study
13.5 mg/ml stock solution of Cy5-BSA in PBS (the labelling protocol is
described further below) were prepared and 48 μl of protein stock so-
lution were pipetted into 552 μl gelator (37 °C), then a stock solution of
5 mg/ml Dil in ethanol was prepared and 3 μl were pipetted into 600 μl
of warm gelator.
4.3. Release studies of proteins
500 μL of gel containing protein in 2 ml HPLC vials were incubated
with 1 ml PBS at 37 °C. The supernatant was removed at different time
points (1, 2, 4, 6, 14 and 24 h) and replaced with fresh PBS. The protein
concentration was determined using the Bradford colorimetric assay
[41]. For lysozyme and β-lactoglobulin, 20 μl of supernatant at each
time point was premixed with 200 μl Bradford reagent, for Bovine
Serum Albumin 20 μl of supernatant were premixed with 200 μl of
Bradford reagent and for Insulin 100 μl of supernatant with 100 μl of
Bradford reagent and absorbance at 595 nm was measured using a
Tecan Spark 10 M/ 20 M plate reader. Ratios of supernatant: reagent
were determined in order to provide with a linear calibration curve
(Supplementary Information Fig. S11). For each data point an average
of 4 repeats is presented for the calibration curve and an average of 3
repeats for the protein release study.
4.4. Gel degradation study
500 μL of gel in 2 ml HPLC vials were incubated with 1 ml PBS at
37 °C. The supernatant was removed at different time points (the same
as the protein release study; 1, 2, 4, 6, 14 and 24 h) and replaced with
fresh PBS. 40 μl of supernatant were premixed with 160 μl of methanol
and the absorbance was measured at 295 nm in a quartz 96 well-plate
using a Tecan Spark 10 M/ 20 M plate reader. For each data point an
average of 4 repeats is presented for the calibration curve
(Supplementary Information Fig. S9) and an average of 3 repeats for the
gel degradation study.
4.5. Fluorescence spectroscopy
600 μL of gel (with or without proteins prepared as explained
above) were added to a 2 mm path length cuvette. Fluorescence spectra
were recorded at a Cary Eclipse fluorescence spectrophotometer. The
spectra were recorded with a scan rate of 30 nm/min, averaging time
1 s, and data interval 0.5 nm using different emission and excitation
slits; for BSA (excitation slit 2.5 nm and emission slit 5 nm), β-lacto-
globulin (excitation slit 5 nm and emission slit 5 nm), lysozyme (ex-
citation slit 2.5 nm and emission slit 5 nm), insulin (excitation slit 5 nm
and emission slit 5 nm). Samples were excited in all cases at 275 nm
and 295 nm. Gels (concentration 5 mg/ml) with proteins (30 μM) were
prepared and compared to protein solution in PBS (30 μM for all pro-
teins apart from insulin that is 3 μM).
4.6. Fluorescence microscopy
15 μl of warm gelator solution (concentration 0.5% w/v) where the
encapsulating molecule has already been added were pipetted in the
well and the first image (t = 0 min) was recorded. 400 μl of PBS were
added and the well was transferred to 37 °C and images were recorder
at t = 10 min, 24 h, 48 h.
Gels were made and imaged in Cellview multiwell, glass bottom
slides (0.17 mm, category 1.5, product no: 543079). Fibers / gels and
suspensions were visualized and scanned with the confocal unit of a
Zeiss Elyra PS1 LSM780 microscope. Two different objectives were
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used, water immersion C-Apochromat 63x/1.2 W Korr M27 for scan-
ning the gels and solutions labelled with fluorescamine, and alpha-Plan-
Apochromat 100x/1.46 oil objective for Dil and Cy5 labelled proteins
and time laps experiments. Fluorescent dyes were detected with the
following settings: for fluorescamine, 405 nm laser was set to 0.8%,
emission detected at: 490–624 nm, channel colour (LUT) was set to
green; for Cy5 labelled proteins, 647 nm laser was set to 4%, emission
detected at 654–752 nm, channel colour (LUT) was set to magenta; for
Dil, 561 nm laser was set to 0.1%, emission detected at 561–624 nm. To
reduce noise, and reveal more details, for all the scans line averaging of
2, and slow scan of 6.3 μs dwell time was applied during scanning.
Images and videos were exported using Zeiss Zen 2012 SP5, histogram
values (display of the image brightness) was set to the same for the
samples belonging to the same experiment.
4.7. Protein labelling
0.4 mg Cyanine5 NHS ester were dissolved in 200 μl DMSO and
6 mg Bovine Serum Albumin were dissolved in 1800 μl NaHCO3 0.1 M
(pH 8.3). The reaction was left under stirring overnight and the mixture
was left to dialyse for 7 days using a 3.5 kDa dialysis tubing. After
dialysis, the labelled protein was analysed by size exclusion chroma-
tography (SEC) using a TSK gel G3000SWXL (300 × 7.8 mm) column
(TOSOH, Tokyo, Japan), running on a HPLC system. The protein was
isocratically eluted in DPBS at a flow rate of 1 ml min−1. Fluorescence
was recorded at λem =666 nm, with excitation fixed at λex =644 nm.
The chromatogram is presented in Fig. S14.
4.8. Enzymatic degradation study
120 μL of warm gelator solution (0.5% w/v) in different buffers
[50 mM KH2PO4 (pH = 4.5) for pepsin and PBS for chymotrypsin]
were pipetted into 1.5 ml plastic Eppendorf tubes and Bovine Serum
Albumin (in PBS) was added, as described earlier, to achieve a final
concentrations of 30 μM. 10 μL (5 mg/ml) of pepsin and 20 μl (2 mg/
ml) were pipetted on top of the already formed gel and incubated for
1 h, 4 h and 24 h at 37 °C. Enzyme concentrations were selected in
order to allow us to qualitatively assess the prevention of protein de-
gradation, in a time course of 24 h. At the previously mentioned time
points, the enzymes were quenched after the addition of 80 μl SDS-
PAGE Reducing Sample Buffer (RSB), plus 10 μl of HCl 1 M in the case
of chymotrypsin, and the samples were denatured by heating at 100 °C
for 5 min prior to gel loading. 10 μL of sample were pipetted into a
4–20% Mini-PROTEAN® TGX™ Precast Protein Gel which was run in a
standard running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS). Gels
were incubated in InstantBlue® (Expedeon, UK). RSB contained 75 mM
Tris–HCl pH 6.8, 10% glycerol, 2% SDS, 0.05% bromophenol blue,
2.5% β-mercaptoethanol.
4.9. Samples for dmall angle X-ray scattering (SAXS)
Samples for small angle X-ray scattering (SAXS) were prepared in
1.5 mm borosilicate glass capillaries (Capillary Tube Supplies Ltd) and
sealed with a UV-curable adhesive (Norland Optical Adhesive). SAXS
measurements were taken on a SAXSLab Ganesha 300XL instrument
using a CuKα source (1.54 Å) and a Pilatus 300 K detector. Data col-
lection was performed over a Q range of 0.007–0.25 Å−1, with an ex-
posure time of 7200 s per sample. A correction for tube thickness and
curvature was applied during measurement, and a capillary of buffer
was run in order to perform background subtraction. The data were
fitted using the SasView 4.1 software package.
4.10. Atomic force microscopy
Gel solutions were prepared as previously described for the gel
degradation study (see ‘Gel degradation study’ section). The
supernatant after 4 h incubation was extracted and 40 μl were pippeted
onto mica. Mica was transferred on preheated at 37 °C AFM stage.
Adequate amount (approximately 50 μl) of PBS were added to immerse
fully the AFM tip in liquid. Imaging was performed under Peak Force
mode using the Bruker FastScan Dimension with ScanAnalyst AFM.
4.11. Lysozyme functionality assay
A turbidimetric enzymatic assay was performed by measuring the
decrease in optical density of an aqueous suspension of Micrococcus
lysodeikticus lyophilised cells, a natural substrate for lysozyme, in PBS.
Gel with lysozyme was prepared as described before and 0.5 ml of gel
was incubated with 1 ml of PBS at 37 °C for 24 h until gel erosion. The
final concentration of lysozyme in the dispersion produced was 37 μg/
mL. PBS (20 mL) solution was added to 10 mg of lyophilised cells.
300 μl of this substrate suspension were added to 150 μl of solution and
the decrease in optical density at λ =460 nm was measured as a
function of time. Free gelator and free lysozyme were used as controls
at the same concentration as in the samples after incubation at the same
conditions as lysozyme in the gel. All kinetic experiments were carried
out in triplicate.
4.12. Evaluation of the insulin bioactivity in human cells
The HepG2 cell line was obtained from ECACC (UK, distributed by
SIGMA) and cultured in growth medium: EMEM (1 g glucose/L, SIGMA,
UK) supplemented with 10% FBS (GIBCO, Thermo South America), 1%
Non-essential amino acids (GIBCO, Thermo Grand Island USA), 2 mM L-
Glutamine (SIGMA Brazil), 1% Penicillin-Streptomycin (SIGMA Israel).
HepG2 originated from a human liver carcinoma, a bona-fide insulin
target organ, and are enriched in Insulin Receptor expression (https://
www.proteinatlas.org/ENSG00000171105-INSR/cell). Cells were pas-
saged once per week by trypsinization (10x Trypsin solution, SIGMA
USA) for 5 min and passage through an 18 gauge needle to obtain a
single cell suspension. They were used between passages 3 and 20.
For transfection, Viafect (Promega, Madison USA), and Turbofect
(Thermo, Lithuania) were compared by measuring the efficiency of
transfection of a commercial plasmid preparation of pMAXGFP (Lonza,
Köhln Germany) following the standard recommended protocols.
Efficiency was calculated measuring the number of GFP fluorescent
cells respect to the total number of cells stained with Hoescht 33258
(SIGMA Israel). Apoptosis measured as condensed Hoescht + cells was
also measured and discarded for efficiency. Since Viafect obtained
a> 95% efficiency while Turbofect approached 65%, all subsequent
experiments were performed using Viafect.
MW48 plates (Costar, Thermo NY USA) were previously coated with
100 μg/ml Type I collagen solution in PBS (stock solution: 4 mg/ml,
SIGMA St Louis MO USA) and washed three times with PBS (SIGMA St
Louis MO USA). For each assay, 24000 HepG2 cells/well were seeded
on these wells in growth medium, and allowed to grow for one full day.
Next day, a transfection mix of DNA plasmid (85 ng of promoter+35 ng
empty RSV plasmid/well), Viafect transfection reagent (1.5 μL/well)
and EMEM (23.5 μL/well) was prepared for all wells combined and
incubated for 20 min. The plasmids used were: pSynSRE-T-luc
(Addgene, Cambridge USA) containing the −324 to −225 bp fragment
of the hamster HMG-CoA synthase promoter containing the SRE ele-
ments upstream of the minimal HMG-CoA synthase TATA box (−28 to
+39) pSynSRE-Mut-T-luc bearing four point mutations in that pro-
moter SRE elements [44,45]. It has been previously shown that Insulin
regulates HMG-CoA synthase expression through those SRE sites in
human cells, and its action abolished in the mutated promoter [46].
Meanwhile, cell medium was replaced by growth medium plus
2 mM metformin (SIGMA, Steinheim Germany). Metformin helps to
reduce the basal luciferase expression while the cells were under
transfection. Subsequently, 25 μl of the transfection mix was pipetted
per well and incubated during 6 h. After three washes with warm PBS
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were performed and changed to deprived medium (as growth medium
but with only 0.5% FBS) including the insulin/vehicle to test (5–200
μIU/ml or equivalent vehicle volume). Each condition was tested in six-
eight replicates. After 20 h, wells were washed three times with PBS
followed by addition of 40 μl PassiveLysis Buffer/well (Promega,
Madison USA) for 20 min. Lysates were collected and frozen at −20 °C.
Luciferase activity was assayed as described[56] using 15 μL of lysate in
a Mithras microplate reader (LB940, Berthold, Bad Wildbad Germany).
Experiments were repeated three times.
Statistics and figures were performed with GraphPad 7 by applying
first a Kolmogorov-Smirnov normality test and, being normally dis-
tributed, following by an unpaired t-test to assess significance. Insulin
–Vehicle concentrations were plotted in parallel graphics comparing the
normal SynSRE-T-luc and the mutated SynSRE-Mut-T-luc promoter (SI,
Fig. S6).
4.13. Rheology studies
Rheology was carried out using an Anton Paar MCR302 Modular
Compact Rheometer. A four bladed vane geometry was used with a
diameter of 8.5 mm and length 8.5 mm in a cup with a diameter of
14.5 mm. The solution of gelator was prepared in 7 ml aluminium cups
to a final sample volume of 2 mL, as per the method described above.
Once the gel was prepared, the sample vial was mounted in the lower
plate (cup) of the rheometer; the vane (attached to the upper part) was
lowered into place, at a depth of 2 mm. This arrangement gave a total
sample depth of approximately 16 mm in the 14.5 mm diameter cup
which allowed positioning of the vane in the centre of the sample. All
rheological measurements were carried out in 7 ml aluminium vials to
allow for heating at 37 °C of the sample prior to measurement. Time
dependant recovery measurements were carried out by alternating the
strain between 5% and 500%; conditions that could guarantee a stable
gel at the lower strain and complete deformation at the higher strain.
The strains were applied in 20 min (0.2%) and 30 s (500%), followed by
30 min (0.2%) cycles. The frequency (5 rad/sec) and temperature
(37 °C) were kept constant throughout.
4.14. In vivo study
This study was conducted under the Animals (Scientific Procedures)
Act 1986 UK Home Office Licence number PPL P435A9CF8, 19b and
given ethical approval by the University of Nottingham AWERB. NCRI
guidelines for the welfare and use of animals in cancer research, LASA
good practice guidelines and FELASA working group on pain and dis-
tress guidelines were followed. ARRIVE Guidelines were followed in the
reporting of the animal studies. 12 female CD-1 NuNu mice (12 weeks
old) were obtained from Charles River (UK). Mice were maintained in
IVCs (Tecniplast UK) within a barriered unit illuminated by fluorescent
lights set to give a 12 h light-dark cycle (on 07.00, off 19.00), as re-
commended in the United Kingdom Home Office Animals (Scientific
Procedures) Act 1986. The room was air-conditioned by a system de-
signed to maintain an air temperature range of 21 ± 2 °C and a hu-
midity of 55% + 10%. Mice were housed in social groups during the
procedure with irradiated bedding and provided with autoclaved
nesting materials and environmental enrichment. Daily monitoring of
general health and well-being and weights was undertaken.
After injections of the different formulations, fluorescence signal
was measured at 0 h, 1 h, 2 h, 4 h, 24 h and 72 h followed by weekly
imaging through IVIS Spectrum. The gels were prepared with a con-
centration 5 mg/ml of gelator, 0.025 mg/ml Dil or 1 mg/ml Cy5-BSA.
The gel containing Dil contained 0.5% v/v ethanol in order to solubilise
the hydrophobic dye. 4 different groups of mice were used: (1) gels
containing Dil, (2) gels containing Cy5-BSA, (3) gel alone, and (4) Cy5-
BSA in solution.
For the data processing the Living Image Software was used.
Rectangular regions of interest (ROI) were drawn including the area
occupied by the gel at t = 0 h. The same ROIs were used for the other
time points. Fluorescence intensity values were extracted in radiance
(ρ/sec/cm2/sr) and presented in the same colour scale.
4.15. Inflammation markers at the site of injection
Skin was excised from around the injection site including the area in
which the gel had resided. All samples (samples with gel, N = 3 and a
control with no gel injected) were embedded in optimal cutting tem-
perature (OCT) compound using liquid nitrogen cooled isopentane.
Serial sections 7 μm thick were cut from each block throughout the
entire tissue on a crystat (Leica, Germany) and mounted on poly-
silinated microscope glass slides (Menzel Gläser Polysine®; Thermo-
Scientific, Germany). Following embedding and sectioning, tissue sec-
tions were fixed in 4% paraformaldehyde for 5 min and stained using
haematoxylin and eosin (H&E). H&E staining was achieved by immer-
sing samples for 2.5 min in haematoxylin, 15 s in 1% acetic industrial
methylated spirits, 15 s in ammoniated water and 4 min in eosin.
Following staining were dehydrated through an ethanol series (50, 70,
90, 95 and 100% ethanol for 5 min each followed by 2X xylene im-
mersions) and glass coverslips were mounted using DPX. Following
staining, tissue and cell morphology was analysed throughout the tissue
samples. The observer was blinded to the sample identification to avoid
subconscious bias. Images were captured using a Leica CTR500 mi-
croscope (Leica Microsystems, Germany) with bright field light. For
each sample several sections 200 μm apart were analysed at 5X, 10X,
20X, 40X and 60X magnifications and photomicrographs captured.
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